Table 2.
Number of patients experiencing acute adverse events at least possibly related to bevazicumab in combination with concurrent cisplatin and radiation therapy
| Bevacizumab dose | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 5 mg/kg (n = 3) |
10 mg/kg (n = 2) |
15 mg/kg (n = 5) |
|||||||
| Grade | |||||||||
| Adverse event | 2 | 3 | 4 | 2 | 3 | 4 | 2 | 3 | 4 |
| Hematologic | |||||||||
| Leukopenia | 1 | - | - | 1 | - | - | - | 1 | - |
| Neutropenia | - | - | - | - | - | - | - | 1 | - |
| Nonhematologic | |||||||||
| Mucositis | 1 | 3 | - | - | 2 | - | 2 | 3 | - |
| Dysphagia | - | 3 | - | - | 2 | - | 2 | 3 | - |
| Tumor pain | - | 1 | - | 1 | 1 | - | 3 | - | - |
| Hypertension | - | 1 | - | 2 | - | - | 2 | - | - |
| Cellulitis | 1 | - | - | - | - | - | - | - | - |
| Weight loss | 1 | 2 | - | - | 1 | - | 3 | - | - |
| Fatigue | 2 | - | - | 1 | - | - | 1 | - | - |
| Dehydration | - | 1 | - | 2 | - | - | - | 1 | - |
| Nausea | 1 | 1 | - | - | 1 | - | 1 | - | - |
| Emesis | - | 1 | - | 1 | - | - | 3 | - | - |
| Oral pain | - | - | - | - | - | - | 1 | 1 | - |
| Skin reaction | - | - | - | - | 1 | - | - | - | - |
| Gastritis | - | - | - | 1 | - | - | - | - | - |
| Dysgeusia | - | - | - | - | - | - | 2 | - | - |
| Hyponatremia | - | - | - | - | - | - | - | 1 | - |
| Candidiasis | 2 | - | - | - | - | - | - | - | - |
| Diarrhea | - | - | - | - | - | - | 1 | - | - |
| Anorexia | - | 1 | - | - | - | - | - | - | - |
| Thrombosis | - | - | - | - | - | - | - | 1 | - |
| Hemorrhage, oral cavity | - | - | - | - | - | - | 1 | - | - |
| Leg edema | - | - | - | - | 1 | - | - | - | - |